ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice.
ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice.
复制标题
DOI:
10.1038/s41598-017-05190-7
复制
发表时间:
2017-07-14
影响因子:
4.6
通讯作者:
Lu J
中科院分区:
文献类型:
--
作者:
Sun Q;Wang Y;Zhang J;Lu J
Protease-activated receptor 2 (PAR-2) plays an important role in the pathogenesis of liver fibrosis. We studied the effect of N1-3-methylbutyryl-N4-6-aminohexanoyl-piperazine (ENMD-1068), a PAR-2 antagonist, on the development of CCl4-induced liver fibrosis in mice and activation of hepatic stellate cells (HSCs) isolated from the mice. Before CCl4 injection, the mice were injected intraperitoneally with either 25 mg/kg or 50 mg/kg ENMD-1068 or with 200 μL of the vehicle control twice per week for 4 weeks. The isolated HSCs were stimulated by TGF-β1 with or without ENMD-1068 to evaluate the role of PAR-2 in TGF-β1 induced HSCs activation and collagen production. We showed that the levels of ALT/AST, collagen content, and α-smooth muscle actin (α-SMA) were significantly reduced by treatment with ENMD-1068 in CCl4-induced fibrotic mice. Interestingly, we found TGF-β1 signaling-related expression levels of α-SMA, type I and III collagen, and C-terminal phosphorylation of Smad2/3 were significantly decreased in the ENMD-1068 treated HSCs. Moreover, we showed ENMD-1068 treatment inhibited trypsin or SLIGRL-NH2 stimulated calcium release and TGF-β1 induced Smad transcriptional activity in HSCs. We demonstrated that ENMD-1068 reduces HSCs activation and collagen expression through the inhibiton of TGF-β1/Smad signal transduction.
登录
查看更多内容
影响因子:
82.9
作者:
Mehal, Wajahat Z.;Iredale, John;Friedman, Scott L.
通讯作者:
Friedman, Scott L.
影响因子:
5.8
作者:
Xu, Tianjiao;Pan, Zhi;Niu, Yingcai
通讯作者:
Niu, Yingcai
影响因子:
4.8
作者:
Chung, Hyunjae;Ramachandran, Rithwik;Muruve, Daniel A.
通讯作者:
Muruve, Daniel A.
影响因子:
9.8
作者:
Wang, Yifeng;Lin, Min;Liu, Fenghua
通讯作者:
Liu, Fenghua
影响因子:
7.3
作者:
Navarro-Nunez, L.;Rivera, J.;Lozano, M. L.
通讯作者:
Lozano, M. L.